Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced or metastatic adenocarcinoma of the stomach~* ECOG performance scale ≤ 2~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Adequate hepatic, renal, heart, and hematologic functions:~  * platelets\>80 × 109/L~ * neutrophil\>2.0 × 109/L~ * serum creatinine ≤ 1.5mg/dl~ * total bilirubin within upper limit of normal(ULN)~ * serum transaminase ≤ 2.5 × the ULN~Exclusion Criteria:~* Pregnant or lactating women~* Concurrent cancer~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Neuropathy, brain, or leptomeningeal involvement~* Uncontrolled significant comorbid conditions and previous radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).